Usona Institute
🇺🇸United States
- Country
- 🇺🇸United States
- Ownership
- Private
- Established
- 2014-01-01
- Employees
- 11
- Market Cap
- -
Psilocybin for Major Depressive Disorder (MDD)
Phase 3
Recruiting
- Conditions
- Depressive Disorder, Major
- Interventions
- First Posted Date
- 2024-03-13
- Last Posted Date
- 2025-01-28
- Lead Sponsor
- Usona Institute
- Target Recruit Count
- 240
- Registration Number
- NCT06308653
- Locations
- 🇺🇸
VA Nebraska Western Iowa Health Care System, Omaha, Nebraska, United States
🇺🇸University of Alabama Clinical Research Unit, Birmingham, Alabama, United States
🇺🇸Preferred Research Partners-NWA, LLC, Fayetteville, Arkansas, United States
Pharmacokinetics, Safety, and Tolerability of Intramuscular 5-MeO-DMT in Healthy Volunteers
Phase 1
Completed
- Conditions
- PharmacokineticsSafetyTolerability
- Interventions
- First Posted Date
- 2023-01-26
- Last Posted Date
- 2023-11-30
- Lead Sponsor
- Usona Institute
- Target Recruit Count
- 54
- Registration Number
- NCT05698095
- Locations
- 🇺🇸
Altasciences Clinical Kansas, Inc, Overland Park, Kansas, United States
An Evaluation of Psilocybin's Effect on Cardiac Repolarization and the Effect of Food on Psilocybin's Pharmacokinetics
Phase 1
Completed
- Conditions
- QTc IntervalPharmacokinetics
- Interventions
- First Posted Date
- 2022-07-28
- Last Posted Date
- 2023-08-15
- Lead Sponsor
- Usona Institute
- Target Recruit Count
- 60
- Registration Number
- NCT05478278
- Locations
- 🇺🇸
Altasciences Clinical Kansas, Inc, Overland Park, Kansas, United States
PSIL201 Long-term Follow-up Study: Psilocybin or Niacin / Major Depressive Disorder
Terminated
- Conditions
- Major Depressive Disorder
- Interventions
- Other: No intervention will be administered as part of this study.
- First Posted Date
- 2020-04-21
- Last Posted Date
- 2022-12-02
- Lead Sponsor
- Usona Institute
- Target Recruit Count
- 24
- Registration Number
- NCT04353921
- Locations
- 🇺🇸
Segal Trials, Lauderhill, Florida, United States
A Study of Psilocybin for Major Depressive Disorder (MDD)
Phase 2
Completed
- Conditions
- Depressive Disorder, Major
- Interventions
- First Posted Date
- 2019-03-07
- Last Posted Date
- 2023-06-05
- Lead Sponsor
- Usona Institute
- Target Recruit Count
- 104
- Registration Number
- NCT03866174
- Locations
- 🇺🇸
Johns Hopkins University, Baltimore, Maryland, United States
🇺🇸Cedar Clinical Research, Draper, Utah, United States
🇺🇸Hassman Research Institute, Berlin, New Jersey, United States
© Copyright 2025. All Rights Reserved by MedPath